Tech Company Financing Transactions
Pharmasset Funding Round
Pharmasset, based in Princeton, secured $40 million from Burrill & Company, MDS Capital and MPM Capital.
Transaction Overview
Company Name
Announced On
8/10/2004
Transaction Type
Venture Equity
Amount
$40,000,000
Round
Series D
Investors
Proceeds Purpose
Pharmasset will use the proceeds of this investment to continue advancing our clinical programs, supporting discovery research, and expanding the company's infrastructure.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
303-A College Road East
Princeton, NJ 08540
USA
Princeton, NJ 08540
USA
Phone
Website
Email Address
Overview
Pharmasset, Inc. is an emerging pharmaceutical company committed to the discovery, development, and commercialization of novel antiviral drugs. The company leverages its expertise in nucleoside chemistry to develop therapeutics to combat infections caused by drug-resistant human immunodeficiency virus (HIV) and hepatitis viruses.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Schaefer Price
Chief Financial Officer
Kurt Leutzinger
Chief Medical Officer
Michelle Berrey
Chief Scientific Officer
Michael Otto
VP - Bus. Development
Abel Rosa
VP - Sales
Patrick Higgins
Browse more venture capital transactions:
Prev: 8/9/2004: Firetide venture capital transaction
Next: 8/10/2004: Nouvoyance venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs